Cancer-associated venous thrombosis in adults (second edition): A British Society for Haematology Guideline

Raza Alikhan; Keith Gomez; Anthony Maraveyas; Simon Noble; Annie Young; Mari Thomas; British Society for Haematology

doi:10.1111/bjh.19414

Cancer-associated venous thrombosis in adults (second edition): A British Society for Haematology Guideline

Br J Haematol. 2024 Apr 25. doi: 10.1111/bjh.19414. Online ahead of print.

Authors

Raza Alikhan^{1

2}, Keith Gomez³, Anthony Maraveyas⁴, Simon Noble², Annie Young⁵, Mari Thomas⁶; British Society for Haematology

Affiliations

¹ University Hospital of Wales, Cardiff, UK.
² Division of Population Medicine, Cardiff University School of Medicine, Cardiff, UK.
³ Haemophilia Centre and Thrombosis Unit, Royal Free London NHS Foundation Trust, London, UK.
⁴ Centre for Clinical Sciences, The Hull York Medical School, York, UK.
⁵ Warwick Medical School, University of Warwick, Coventry, UK.
⁶ University College London Hospitals NHS Foundation Trust, London, UK.

PMID: 38664942
DOI: 10.1111/bjh.19414

Abstract

A shared decision on the most appropriate agent for the treatment of cancer-associated thrombosis should consider the following factors, which should be reassessed as patients continue along their cancer care pathway: risk of bleeding; tumour site; suitability of oral medications; potential for drug-drug interactions; and patient preference and values regarding choice of drug. Continuing anticoagulation beyond 6 months in patients with cancer-associated venous thromboembolism and active cancer is recommended.

Keywords: anticoagulation; cancer; venous thromboembolism; venous thrombosis.